US presidential candidate Hillary Clinton vows crackdown on 'unjustified' drug price hikes
US Democratic presidential nominee Hillary Clinton is offering a plan to protect Americans from unjustified price hikes in lifesaving treatments that have long been on the market.
Over the last year, we’ve seen far too many examples of drug companies raising prices excessively for treatments that have been available for years – from Turing raising the price of pyrimethamine for AIDS patients by over 5,000%, to Mylan raising the price of the EpiPen by more than 400%, according to a campaign announcement on Friday, which comes as a US Congressional Committee launches an investigation into the pricing of the EpiPen injector by drugmaker Mylan
Should an excessive, outlier price increase be determined for a long-standing treatment, Mrs Clinton’s plan would make new enforcement tools available, including:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze